drugset
drugset / Trial / NCT05147753

Moxonidine Effects on Neuropeptide Y

NCT05147753 ↗

Phase 4 Completed 90 enrolled Aristotle University Of Thessaloniki
NaSingle-groupOpen-labelTreatment

Summary

Treatment with monotherapy of moxonidine 0.6 mg daily in treatment-naïve subjects with mild or moderate hypertension

Timeline

Start
2010-01-11
Primary completion
2014-06-30
Completion
2014-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Moxonidine Small molecule 0.6 mg —

Indications

hypertensive disorder obesity disorder